Equity Overview
Price & Market Data
Price: $1.20
Daily Change: -$0.04 / 3.33%
Range: $1.15 - $1.25
Market Cap: $12,497,851
Volume: 165,646
Performance Metrics
1 Week: -7.09%
1 Month: -4.07%
3 Months: -41.87%
6 Months: -47.56%
1 Year: -71.77%
YTD: -39.18%
Company Details
Employees: 19
Sector: Health technology
Industry: Medical specialties
Country: United States
Details
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.